This report from Life Science Intelligence provides the latest market data for the Global Neurovascular Devices for Hemorrhagic Stroke Market. Information covered by this report includes:
· unit volumes & pricing forecast from 2019-2024
· analyses of the leading companies, and
· global market share analysis.
The global market for neurovascular devices for the treatment of hemorrhagic stroke was valued at an estimated $1.7 billion in 2020 and is projected to increase at a CAGR (2020-2024) of 6.6%. Product segments covered by this report include neurovascular microcatheters, guidewires, guide catheters, sheaths, stents, thrombectomy devices, embolization devices and materials, flow diverting devices, neurovascular clips.
This report covers the impact of COVID-19 on the neurovascular devices for hemorrhagic stroke market, including a recent forecast from 2020 to 2024. COVID-19 has also impacted leading competitors, such as Abbott, Boston Scientific, Cardinal Health, Penumbra, Stryker, Terumo, and others. The report provides insights into trends, drivers, and limiters of the neurovascular devices for hemorrhagic stroke market, as well as highlights potential opportunities.
The COVID-19 pandemic had a minimal impact on the market for neurovascular devices for the treatment of ischemic and hemorrhagic stroke. Stroke is a critical condition with a sensitive timeline to treatment to ensure recovery. As such, the receipt of healthcare for the treatment of stroke was not severely impacted by the pandemic.
Stryker, Boston Scientific, and Cardinal Health account for approximately 70% market share of the global neurovascular devices for hemorrhagic stroke. The market is expected to grow further as robotics are introduced for neurovascular procedures. The CorPath GRX system from Corindus Vascular Robotics is expected to revolutionize the treatment for neurovascular stroke as it enables neuro-interventionalists remote access to stroke patients to deliver timely life-saving care.